Avantor® Expands Life Sciences Innovation Center to Address Bioprocessing Needs in Protein Science, Monoclonal Antibodies (mAbs), Cell and Gene Therapy

Increased investment in bioprocessing infrastructure furthers biologics innovation and improved efficiencies in bioproduction

News provided by

Avantor and Financial News

Jun 30, 2020, 08:25 ET

RADNOR, Pa., June 30, 2020 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced the expansion of the company's Bridgewater, N.J. (USA) innovation center. Located close to biotech companies, the site now has nearly double the laboratory and support space.

Bioprocessing efficiency that doesn't compromise quality continues to be a top priority for the biopharma industry. At the same time, it's critical to meet increasingly stringent global regulatory standards.

"Innovation is about solving customer problems in a rapidly progressing biotechnology environment using contemporary technologies and thinking," said Dr. Ger Brophy, Executive Vice President, Biopharma Production at Avantor. "We collaborate with our customers from their initial discovery and development activities through scale-up and commercialization. Our solutions support industry downward cost pressure by emphasizing supply chain efficiency and improving production process performance."

Avantor's expanded innovation center enhances the Company's R&D support for customized product and bioprocess development, and custom cell and gene therapy reagent manufacturing to support customers' therapeutic products that are developed for advancements in personalized medicine.

The site capabilities support new bioprocessing products designed to help minimize risk of contamination and variability for cell and gene therapy (C>), monoclonal antibodies (mAbs) and vaccines, including high purity products, single-use solutions and small volume cGMP reagents in single use bags. The site developed Avantor's recently launched novel J.T.Baker^®BAKERBOND^® PROchievA™ recombinant protein A resin for purifying monoclonal antibodies (mAbs) and other complex molecules.

Monoclonal antibodies (mAbs) are used in a wide variety of clinical indications, including asthma, cancer, Crohn's disease, and rheumatoid arthritis, and most recently being tested for use as a treatment for COVID-19 according to the National Institutes for Health (NIH).

The Bridgewater innovation center expansion follows the December 2019 opening of Avantor's innovation and customer support center in Shanghai, China.

About Avantor
Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. One of our greatest strengths comes from having a global infrastructure that is strategically located to support the needs of our customers. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. For information, visit www.avantorsciences.com and find us on Linkedin, Twitter and Facebook.

Global Media Contact
Robert Donohoe
Senior Director, Corporate Communications
Avantor
M: +1 484-688-4730
[email protected]

SOURCE Avantor and Financial News